Traws Pharma (TRAW) Short Interest Ratio & Short Volume

Short interest is the volume of Traws Pharma shares that have been sold short but have not yet been closed out or covered. As of January 31st, traders have sold 150,800 shares of TRAW short. 5.82% of Traws Pharma's shares are currently sold short. Learn More on Traws Pharma's current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Traws Pharma: Group One Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.82% of Traws Pharma's floating shares are currently sold short.

Traws Pharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 150,800 shares, a drop of 12.3% from the previous total of 171,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Traws Pharma currently has issued a total of 3,650,000 shares. Some of Traws Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Traws Pharma currently has a public float of 2,590,000 shares.

5.82% of Traws Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Traws Pharma: Procaps Group S.A. (0.12%), Enanta Pharmaceuticals, Inc. (16.92%), Journey Medical Co. (0.82%), Skye Bioscience, Inc. (10.22%), Atossa Therapeutics, Inc. (7.35%), XBiotech Inc. (4.65%), Aligos Therapeutics, Inc. (21.83%), Editas Medicine, Inc. (20.70%), Alto Neuroscience, Inc. (17.69%), Anixa Biosciences, Inc. (1.32%),

As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks.

Short selling TRAW is an investing strategy that aims to generate trading profit from Traws Pharma as its price is falling. TRAW shares are trading down $0.21 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Traws Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of TRAW, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TRAW, twice per month. The most recent reporting period available is January, 31 2025.